39.30
0.33 (0.85%)
| Previous Close | 38.97 |
| Open | 39.20 |
| Volume | 1,044,500 |
| Avg. Volume (3M) | 822,321 |
| Market Cap | 3,566,310,400 |
| Price / Sales | 6.25 |
| Price / Book | 25.69 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 - 5 May 2025 |
| Profit Margin | -93.04% |
| Operating Margin (TTM) | -102.62% |
| Diluted EPS (TTM) | -5.83 |
| Quarterly Revenue Growth (YOY) | 28.00% |
| Total Debt/Equity (MRQ) | 588.24% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -389.94 M |
| Levered Free Cash Flow (TTM) | -172.94 M |
| Return on Assets (TTM) | -24.51% |
| Return on Equity (TTM) | -377.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Ultragenyx Pharmaceutical Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.70 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.20% |
| % Held by Institutions | 98.45% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Morgan Stanley, 65.39%) | Buy |
| 65.00 (William Blair, 65.39%) | Buy | |
| Median | 65.00 (65.39%) | |
| Low | 64.00 (Guggenheim, 62.85%) | Buy |
| Average | 64.67 (64.56%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 35.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 20 Jun 2025 | 64.00 (62.85%) | Buy | 37.14 |
| William Blair | 28 May 2025 | 65.00 (65.39%) | Buy | 34.35 |
| Morgan Stanley | 09 May 2025 | 65.00 (65.39%) | Buy | 35.11 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Jun 2025 | Announcement | Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome |
| 20 Jun 2025 | Announcement | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Jun 2025 | Announcement | Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference |
| 20 May 2025 | Announcement | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 14 May 2025 | Announcement | Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report |
| 07 May 2025 | Announcement | Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference |
| 06 May 2025 | Announcement | Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update |
| 30 Apr 2025 | Announcement | Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update |
| 22 Apr 2025 | Announcement | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |